(NASDAQ: IOVA) Iovance Biotherapeutics's forecast annual revenue growth rate of 53.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Iovance Biotherapeutics's revenue in 2025 is $212,679,000.On average, 5 Wall Street analysts forecast IOVA's revenue for 2025 to be $97,003,932,211, with the lowest IOVA revenue forecast at $90,906,958,173, and the highest IOVA revenue forecast at $100,313,889,855. On average, 5 Wall Street analysts forecast IOVA's revenue for 2026 to be $183,414,797,797, with the lowest IOVA revenue forecast at $150,270,474,150, and the highest IOVA revenue forecast at $211,747,794,797.
In 2027, IOVA is forecast to generate $253,264,187,460 in revenue, with the lowest revenue forecast at $207,039,319,940 and the highest revenue forecast at $298,139,960,057.